These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. Peyronie's disease: Contemporary evaluation and management. Ziegelmann MJ; Bajic P; Levine LA Int J Urol; 2020 Jun; 27(6):504-516. PubMed ID: 32253786 [TBL] [Abstract][Full Text] [Related]
46. Therapeutic advances in the treatment of Peyronie's disease. Yafi FA; Pinsky MR; Sangkum P; Hellstrom WJ Andrology; 2015 Jul; 3(4):650-60. PubMed ID: 26097120 [TBL] [Abstract][Full Text] [Related]
47. The management of Peyronie's disease: evidence-based 2010 guidelines. Ralph D; Gonzalez-Cadavid N; Mirone V; Perovic S; Sohn M; Usta M; Levine L J Sex Med; 2010 Jul; 7(7):2359-74. PubMed ID: 20497306 [TBL] [Abstract][Full Text] [Related]
48. The medical management of Peyronie's disease. Akin-Olugbade Y; Mulhall JP Nat Clin Pract Urol; 2007 Feb; 4(2):95-103. PubMed ID: 17287870 [TBL] [Abstract][Full Text] [Related]
53. [Iontophoresis in the conservative treatment of Peyronie's disease: preliminary experience]. Treffiletti S; Annoscia S; Montefiore F; Boccafoschi C Arch Ital Urol Androl; 1997 Dec; 69(5):323-7. PubMed ID: 9477619 [TBL] [Abstract][Full Text] [Related]
54. Effectiveness of antioxidants (propolis, blueberry, vitamin E) associated with verapamil in the medical management of Peyronie's disease: a study of 151 cases. Paulis G; D'Ascenzo R; Nupieri P; De Giorgio G; Orsolini G; Brancato T; Alvaro R Int J Androl; 2012 Aug; 35(4):521-7. PubMed ID: 21950543 [TBL] [Abstract][Full Text] [Related]
55. Inflammatory mechanisms and oxidative stress in Peyronie's disease: therapeutic "rationale" and related emerging treatment strategies. Paulis G; Brancato T Inflamm Allergy Drug Targets; 2012 Feb; 11(1):48-57. PubMed ID: 22309083 [TBL] [Abstract][Full Text] [Related]
56. Conservative treatment of Peyronie's disease: a guide. Cosentino M; Di Nauta M; Boeri L; Ferraioli G; Lucignani G; Ricapito A; Gadda F; Iafrate M; Mancini M; Dal Moro F; Ruiz-Castañe E; Bettocchi C; Montanari E; Sofikitis N World J Urol; 2024 May; 42(1):317. PubMed ID: 38740620 [TBL] [Abstract][Full Text] [Related]
57. Evaluation of intralesional injection of verapamil in treatment of Peyronie's disease. Heidari M; Nejadi JR; Ghate A; Delfan B; Iran-Pour E J Pak Med Assoc; 2010 Apr; 60(4):291-3. PubMed ID: 20419973 [TBL] [Abstract][Full Text] [Related]
58. Comparative Effectiveness of Intralesional Therapy for Peyronie's Disease in Controlled Clinical Studies: A Systematic Review and Network Meta-Analysis. Russo GI; Cacciamani G; Cocci A; Kessler TM; Morgia G; Serefoglu EC; Albersen M; Verze P; J Sex Med; 2019 Feb; 16(2):289-299. PubMed ID: 30692028 [TBL] [Abstract][Full Text] [Related]
59. Safety and tolerability of local treatment with iloprost, a prostacyclin analogue, in patients with Peyronie's disease: a phase I study. Pavone C; Napoli G; Caruana G; Alonge V; Usala M; Abbadessa D BJU Int; 2012 Jul; 110(1):117-21. PubMed ID: 22176734 [TBL] [Abstract][Full Text] [Related]
60. Predictive Factors of Patients' and Their Partners' Sexual Function Improvement After Collagenase Clostridium Histolyticum Injection for Peyronie's Disease: Results From a Multi-Center Single-Arm Study. Cocci A; Russo GI; Salonia A; Cito G; Regis F; Polloni G; Giubilei G; Cacciamani G; Capece M; Falcone M; Greco I; Timpano M; Minervini A; Gacci M; Cai T; Garaffa G; Giammusso B; Arcaniolo D; Mirone V; Mondaini N J Sex Med; 2018 May; 15(5):716-721. PubMed ID: 29699756 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]